Reaction
Hyperleukocytosis reporting signals
As of the last recalculation, Hyperleukocytosis appears in 863 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is HYDROXYUREA (PRR 70.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Hydroxyurea | 58 | 70.8 | 71.0 |
| Tretinoin | 23 | 70.2 | 70.4 |
| Posaconazole Delayed-Release | 19 | 42.6 | 42.7 |
| Ketoprofen | 21 | 39.5 | 39.6 |
| Desloratadine | 17 | 39.0 | 39.0 |
| Bendamustine Hcl | 23 | 36.7 | 36.8 |
| Posaconazole | 22 | 33.5 | 33.5 |
| Brentuximab Vedotin | 10 | 23.8 | 23.8 |
| Cefuroxime | 10 | 21.3 | 21.3 |
| Azacitidine For | 14 | 18.9 | 18.9 |
| Imatinib | 13 | 18.0 | 18.0 |
| Fludarabine Phosphate | 27 | 17.1 | 17.1 |
| Rifampicin | 7 | 16.8 | 16.8 |
| Azacitidine | 20 | 16.6 | 16.6 |
| Linezolid | 20 | 16.6 | 16.6 |
| Blinatumomab | 7 | 16.3 | 16.3 |
| Cytarabine | 37 | 15.5 | 15.5 |
| Cladribine | 6 | 15.2 | 15.2 |
| Meropenem | 19 | 14.6 | 14.6 |
| Micafungin Sodium | 5 | 14.3 | 14.3 |
| Vincristine Sulfate | 17 | 14.3 | 14.3 |
| Ifosfamide | 10 | 11.3 | 11.4 |
| Acalabrutinib | 5 | 10.0 | 10.0 |
| Polatuzumab Vedotin | 4 | 9.9 | 9.9 |
| Venetoclax | 23 | 9.2 | 9.2 |
| Remdesivir | 5 | 9.1 | 9.1 |
| Bendamustine Hydrochloride | 4 | 8.1 | 8.1 |
| Pazopanib Hydrochloride | 8 | 7.2 | 7.2 |
| Durvalumab | 6 | 7.2 | 7.2 |
| Pegfilgrastim | 28 | 7.0 | 7.0 |